HuCART19-IL18 for relapsed/refractory follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR T-cell therapy (huCART19-IL18) for people with follicular lymphoma that has not responded to or returned after at least two prior treatments. It aims to see if adding IL-18 makes the therapy more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have follicular lymphoma (grades 1-3A) that came back or did not respond after at least 2 treatments.
- One of your past treatments must have included an anti-CD20 antibody (like rituximab) and a chemotherapy drug (like cyclophosphamide).
- Your lymphoma must have gotten worse within 2 years after your second or later treatment.
- You must be in reasonably good health (able to care for yourself and do light activity) and have adequate heart, lung, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
This trial tests a new type of CAR-T cell therapy (called L218CAR19) for people with B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help shrink or control the lymphoma.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Relapsed or Refractory Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.